Dedicated to Research Since 1993
  •  

    info@genesismarketinsights.com

Blood Screening Market by Technology (Western Blot Assay, Reverse Polymerase Chain Reaction (RPCR), Enzyme-Linked Immunosorbent Assay (ELISA)), By Product Type (Instruments, Software and Services, Reagents & Kits)- Global size Analysis and Industry Forecast, 2018-2023.

 Healthcare and Pharmaceuticals

Report Overview

Global Blood Screening Market was valued at USD 2.35 Billion in the year 2017. Global Blood Screening Market is further estimated to grow at a CAGR of 4.46% from 2018 to 2023. North America region holds the highest market share in 2017 with APAC region is considered as the fastest growing market in the forecasted period. At a country level, the U.S is the biggest market in 2017 and it is projected to grow at a gradual pace in the coming years.

Grifols (Spain), Roche Diagnostics (Switzerland), bioMérieux (France), Abbott Laboratories (U.S.) are some of the key manufacturers in the Global Blood Screening Market with Roche Diagnostics holding the substantial market share because of its better global presence both at production and at an operational level. Rising research and development expenses to cater changing demand of end users, similarly, growth strategies such as acquisition, merger, and expansion of the distribution network were few techniques adopted by most of Tier 1 and Tier 2 manufacturers in recent years.

Drivers

            Boosting Demand for blood supply

            Increased focus on the safety of blood

Restrain

            Lack of regulatory standards

            Level of required financial investment & lack of technical expertise

Opportunity

            Rising importance of diagnostics in improving healthcare quality

            Development of emerging markets for NAT technology.

Challenge

            Supply of safe blood

            Intense competition and reduced healthcare reimbursement

The NAT (Nucleic Acid Test) segment is likely to hold the top market share during the forecast period. The growth can be attributed to the increasing number of blood donations, rising incidence of infectious diseases, and increasing capacity (disposable income) to pay for NAT-tested blood.

On the other hand, hospitals & clinical Laboratories for users is expected to grow at the highest CAGR of during the year 2017-2023. Majorly because there is increasing demand for donated blood, growing number of organ transplantation surgeries, rising awareness regarding the safety of blood, increasing number of donations worldwide, and growth in government funding to charitable trusts.

Key Benefits for Stakeholders

Blood screening Manufacturers, Distributors, and Retailers

Research and Consulting organization

Technology Standards Organizations, Forums, Alliances and Associations

End-use industries

Regulatory bodies, policy actors, and consumers.

By Products & Services                                                          

Instruments                  

Software and Services               

Reagents & Kits             

Assays/consumables

By Technology                        

Western Blot Assay                   

Reverse Polymerase Chain Reaction (RPCR)                    

Enzyme-Linked Immunosorbent Assay (ELISA)                

Nucleic Acid Test (NAT)                                                  

Next-Generation Sequencing (NGS)                    

Rapid Tests

By Users                                 

Hospitals                      

Blood Banks

By Region

North America

Europe

Asia-Pacific

RoW

Key Market Players

1. Abbott Laboratories                

2. Ortho Clinical Diagnostics, Inc.            

3. Biomérieux SA                      

4. Grifols SA                 

5. F. Hoffmann-La Roche AG                   

6. Becton, Dickinson, and Company                     

7. Qiagen Netherlands (includes Digene)             

8. Bio-Rad Laboratories, Inc.                  

9. Agilent Technologies (Dako)               

10. Trinity Biotech 

(A brief overview of another 13 companies is also provided) 

Research Methodology:

Genesis Market Insights follows in-depth Research Methodology focused on reducing deviation in the collected data. GMI offers the most precise evaluations and projection for the market numbers. GMI engages following Market Engineering techniques –

  1. Raw Market Data is collected and compared with the Existing in-house Data on a broad front.
  2. Both Bottom-Up and Top-Down approaches are analyzed for segmenting and estimating measurable aspects of the market.
  3. To avoid bias, we filter the collected data collected from authenticated sources.
  4. GMI has a well proven Statistical Modeling System for estimates and forecasts.
  5. Further, the report findings are validated with the Industry Expert Panel on face to face or telephonic interviews.
  6. Panelists are approached from Leading Enterprises across the value chain including manufacturers, suppliers, technology providers, domain experts and buyers so as to validate a thorough and balanced market overview.

Detailed customization is also available for you. Further, if the report listed above does not meet your key requirements. Our customized research report will analytically cover the required market information you need which will help you to plan your business decisions.

Table Of Content

1. Introduction

1.1 Market Vision

       1.1.1 Market Definition

       1.1.2 Market Scope

1.2 Limitations

1.3 Stakeholders

2. Research Methodology

2.1. Research Process

       2.1.1. Secondary Research

             2.1.1.1. Key Data from Secondary Research

       2.1.2. Primary Research

             2.1.2.1. Key Data from Primary Research

             2.1.2.2. Breakdowns of Primary Interviews

2.2. Market Size Estimation

       2.2.1. Bottoms-Up Approach

       2.2.2. Top-Down Approach

       2.2.3. Annual Revenue Process

2.3. Data Triangulation 

2.4. Research Assumptions 

       2.4.1. Assumption

3. Executive Summary

4. Market Overview

4.1. Introduction

4.2. Drivers

4.3. Restraints

4.4. Opportunities

4.5. Challenges

4.6. Regulations

4.7. Supply Chain/Value Chain Analysis

4.8. Patent & Standards

5. Industry Trends

5.1. Introduction

5.2. Porter’s Five Forces Analysis

       5.2.1. Threat of New Entrants

       5.2.2. Threat of Substitutes

       5.2.3. Bargaining Power of Buyers

       5.2.4. Bargaining Power of Suppliers

       5.2.5. Intensity of Competitive Rivalry

6. Blood Screening Market by products & Services                            

6.1 Introduction            

6.2 Instruments            

6.3 Software and Services                     

6.4 Reagents & Kits                   

            6.4.1 ELISA Reagents & Kits       

                        6.4.1.1  Conjugates (Antigen or Antibody-Conjugated Enzyme)

                        6.4.1.2  Sample Diluents and Wash Solutions

                        6.4.1.3  Immunosorbents

                        6.4.1.4  Substrates (Of Enzymes)

                        6.4.1.5  Controls

            6.4.2 NAT Reagents & Kits          

            6.4.3 Other Reagents     

6.5 Assays/consumables

7. Blood Screening Market by Technology                              

7.1 Western Blot Assay              

7.2 Reverse Polymerase Chain Reaction (RPCR)               

7.3 Enzyme-Linked Immunosorbent Assay (ELISA)                       

            7.3.1 Enzyme-Linked Immunosorbent Assay (ELISA) Generation   

            7.3.2 Enzyme-Linked Immunosorbent Assay (ELISA) Platform       

                        7.3.2.1  Fluorescence Immunoassay (FIA)

                        7.3.2.2  Colorimetric Immunoassay (CI)

                        7.3.2.3  Chemiluminescence Immunoassay (CLIA)

7.4 Nucleic Acid Test (NAT)                    

            7.4.1 Real-Time Polymerase Chain Reaction (PCR)           

            7.4.2 Transcription-Mediated Amplification           

7.5 Next-Generation Sequencing (NGS)               

7.6 Rapid Tests

8. Blood Screening Market by Users                           

8.1 Hospitals                 

8.2 Blood Banks

9. Geographical Analysis

9.1. Introduction

9.2. North America

       9.2.1. U.S.

       9.2.2. Canada

       9.2.3. Mexico

9.3. Europe

       9.3.1. Germany

       9.3.2. France

       9.3.3. U.K.

       9.3.4. RoE

9.4. Asia Pacific

       9.4.1. China

       9.4.2. Japan

       9.4.3. India

       9.4.4. RoAPAC

9.5. RoW

       9.5.1. Latin America

             9.5.1.1. Brazil

             9.5.1.2. Argentina

             9.5.1.3. Rest of Latin America

       9.5.2. The Middle East and Africa

10. Company Profiles

(Business Overview, Financial Overview, Product write Up, Recent Developments)

10.1 Abbott laboratories             

10.2 Ortho Clinical Diagnostics, Inc.                    

10.3 Biomérieux SA                   

10.4 Grifols SA              

10.5 F. Hoffmann-La Roche AG               

10.6 Becton, Dickinson and Company                  

10.7 Qiagen Netherlands (includes Digene)                      

10.8 Bio-Rad Laboratories, Inc.              

10.9 Agilent Technologies (Dako)            

10.10 Trinity Biotech

(A brief overview of another 13 companies is also provided) 

11. Competitive Analysis

11.1. Introduction

11.2. Market Positioning of Key Players

11.3 Competitive Strategies Adopted by Leading Players

        11.3.1. Investments & Expansions

        11.3.2. New Product Launches

        11.3.3. Mergers & Acquisitions

        11.3.4. Agreements, Joint Ventures, and Partnerships

12. Appendix

12.1. Questionnaire

12.2. Available Customizations 

12.3. Upcoming Events (Trade Fair, Exhibitions, Conferences)

Summary

No Content Available.